Predicting Glaucoma Progression Requiring Surgery Using Clinical Free-Text Notes and Transfer Learning With Transformers.
AI Summary
Transformer models successfully predicted glaucoma surgery progression from clinical notes, outperforming human review. This offers a promising AI tool to help clinicians tailor treatment for high-risk patients.
Abstract
Purpose
We evaluated the use of massive transformer-based language models to predict glaucoma progression requiring surgery using ophthalmology clinical notes from electronic health records (EHRs).
Methods
Ophthalmology clinical notes for 4512 glaucoma patients at a single center from 2008 to 2020 were identified from the EHRs. Four different pre-trained Bidirectional Encoder Representations from Transformers (BERT)-based models were fine-tuned on ophthalmology clinical notes from the patients' first 120 days of follow-up for the task of predicting which patients would require glaucoma surgery. Models were evaluated with standard metrics, including area under the receiver operating characteristic curve (AUROC) and F1 score.
Results
Of the patients, 748 progressed to require glaucoma surgery (16.6%). The original BERT model had the highest AUROC (73.4%; F1 = 45.0%) for identifying these patients, followed by RoBERTa, with an AUROC of 72.4% (F1 = 44.7%); DistilBERT, with an AUROC of 70.2% (F1 = 42.5%); and BioBERT, with an AUROC of 70.1% (F1 = 41.7%). All models had higher F1 scores than an ophthalmologist's review of clinical notes (F1 = 29.9%).
Conclusions
Using transfer learning with massively pre-trained BERT-based models is a natural language processing approach that can access the wealth of clinical information stored within ophthalmology clinical notes to predict the progression of glaucoma. Future work to improve model performance can focus on integrating structured or imaging data or further tailoring the BERT models to ophthalmology domain-specific text.
Translational relevance: Predictive models can provide the basis for clinical decision support tools to aid clinicians in identifying high- or low-risk patients to maximally tailor glaucoma treatments.
MeSH Terms
Shields Classification
Key Concepts6
The original BERT model, fine-tuned on ophthalmology clinical notes from the first 120 days of follow-up for 4512 glaucoma patients, achieved an AUROC of 73.4% (F1 = 45.0%) for predicting glaucoma progression requiring surgery.
The RoBERTa model, fine-tuned on ophthalmology clinical notes from the first 120 days of follow-up for 4512 glaucoma patients, achieved an AUROC of 72.4% (F1 = 44.7%) for predicting glaucoma progression requiring surgery.
The DistilBERT model, fine-tuned on ophthalmology clinical notes from the first 120 days of follow-up for 4512 glaucoma patients, achieved an AUROC of 70.2% (F1 = 42.5%) for predicting glaucoma progression requiring surgery.
The BioBERT model, fine-tuned on ophthalmology clinical notes from the first 120 days of follow-up for 4512 glaucoma patients, achieved an AUROC of 70.1% (F1 = 41.7%) for predicting glaucoma progression requiring surgery.
All four BERT-based models (original BERT, RoBERTa, DistilBERT, BioBERT) had higher F1 scores (ranging from 41.7% to 45.0%) for predicting glaucoma progression requiring surgery compared to an ophthalmologist's review of clinical notes (F1 = 29.9%) in a cohort of 4512 glaucoma patients.
Out of 4512 glaucoma patients identified from electronic health records between 2008 and 2020 at a single center, 748 patients (16.6%) progressed to require glaucoma surgery.
Related Articles5
Multimodal Artificial Intelligence Models Predicting Glaucoma Progression Using Electronic Health Records and Retinal Nerve Fiber Layer Scans.
Observational StudyPredicting Glaucoma Progression to Surgery with Artificial Intelligence Survival Models.
Observational StudyManagement of the glaucoma patient progressing at low normal intraocular pressure.
ReviewFailure of medical therapy despite normal intraocular pressure.
ReviewThe laser step in early glaucoma.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.